ID   TNR1A_HUMAN             Reviewed;         455 AA.
AC   P19438; A8K4X3; B2RDE4; B3KPQ1; B4DQB7; B4E309; B5M0B5; D3DUR1; Q9UCA4;
DT   01-FEB-1991, integrated into UniProtKB/Swiss-Prot.
DT   01-FEB-1991, sequence version 1.
DT   28-JAN-2026, entry version 271.
DE   RecName: Full=Tumor necrosis factor receptor superfamily member 1A;
DE   AltName: Full=Tumor necrosis factor receptor 1;
DE            Short=TNF-R1;
DE   AltName: Full=Tumor necrosis factor receptor type I;
DE            Short=TNF-RI;
DE            Short=TNFR-I;
DE   AltName: Full=p55;
DE   AltName: Full=p60;
DE   AltName: CD_antigen=CD120a;
DE   Contains:
DE     RecName: Full=Tumor necrosis factor receptor superfamily member 1A, membrane form;
DE   Contains:
DE     RecName: Full=Tumor necrosis factor-binding protein 1;
DE              Short=TBPI;
DE   Flags: Precursor;
GN   Name=TNFRSF1A; Synonyms=TNFAR, TNFR1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND PROTEIN SEQUENCE OF 30-57 AND
RP   252-264.
RX   PubMed=2158862; DOI=10.1016/0092-8674(90)90815-v;
RA   Loetscher H., Pan Y.-C.E., Lahm H.-W., Gentz R., Brockhaus M., Tabuchi H.,
RA   Lesslauer W.;
RT   "Molecular cloning and expression of the human 55 kd tumor necrosis factor
RT   receptor.";
RL   Cell 61:351-359(1990).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Placenta;
RX   PubMed=2158863; DOI=10.1016/0092-8674(90)90816-w;
RA   Schall T.J., Lewis M., Koller K.J., Lee A., Rice G.C., Wong G.H.W.,
RA   Getanaga T., Granger G.A., Lentz R., Raab H., Kohr W.J., Goeddel D.V.;
RT   "Molecular cloning and expression of a receptor for human tumor necrosis
RT   factor.";
RL   Cell 61:361-370(1990).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=1702293; DOI=10.1089/dna.1990.9.705;
RA   Himmler A., Maurer-Fogy I., Kroenke M., Scheurich P., Pfizenmaier K.,
RA   Lantz M., Olsson I., Hauptmann R., Stratowa C., Adolf G.R.;
RT   "Molecular cloning and expression of human and rat tumor necrosis factor
RT   receptor chain (p60) and its soluble derivative, tumor necrosis factor-
RT   binding protein.";
RL   DNA Cell Biol. 9:705-715(1990).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND PROTEIN SEQUENCE OF 41-53;
RP   110-124 AND 199-201 (ISOFORM 1).
RX   PubMed=1698610; DOI=10.1002/j.1460-2075.1990.tb07526.x;
RA   Nophar Y., Kemper O., Brakebusch C., Engelmann H., Zwang R., Aderka D.,
RA   Holtmann H., Wallach D.;
RT   "Soluble forms of tumor necrosis factor receptors (TNF-Rs). The cDNA for
RT   the type I TNF-R, cloned using amino acid sequence data of its soluble
RT   form, encodes both the cell surface and a soluble form of the receptor.";
RL   EMBO J. 9:3269-3278(1990).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Placenta;
RX   PubMed=2170974; DOI=10.1073/pnas.87.19.7380;
RA   Gray P.W., Barrett K., Chantry D., Turner M., Feldman M.;
RT   "Cloning of human tumor necrosis factor (TNF) receptor cDNA and expression
RT   of recombinant soluble TNF-binding protein.";
RL   Proc. Natl. Acad. Sci. U.S.A. 87:7380-7384(1990).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=1315717; DOI=10.1016/0888-7543(92)90226-i;
RA   Fuchs P., Strehl S., Dworzak M., Himmler A., Ambros P.F.;
RT   "Structure of the human TNF receptor 1 (p60) gene (TNFR1) and localization
RT   to chromosome 12p13.";
RL   Genomics 13:219-224(1992).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS LEU-75 AND GLN-121.
RG   SeattleSNPs variation discovery resource;
RL   Submitted (JUL-2002) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1; 2 AND 3).
RC   TISSUE=Neutrophil, Teratocarcinoma, Tongue, and Uterus;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 5).
RX   PubMed=19906316; DOI=10.1186/1471-2164-10-518;
RA   Wang P., Yu P., Gao P., Shi T., Ma D.;
RT   "Discovery of novel human transcript variants by analysis of intronic
RT   single-block EST with polyadenylation site.";
RL   BMC Genomics 10:518-518(2009).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16541075; DOI=10.1038/nature04569;
RA   Scherer S.E., Muzny D.M., Buhay C.J., Chen R., Cree A., Ding Y.,
RA   Dugan-Rocha S., Gill R., Gunaratne P., Harris R.A., Hawes A.C.,
RA   Hernandez J., Hodgson A.V., Hume J., Jackson A., Khan Z.M., Kovar-Smith C.,
RA   Lewis L.R., Lozado R.J., Metzker M.L., Milosavljevic A., Miner G.R.,
RA   Montgomery K.T., Morgan M.B., Nazareth L.V., Scott G., Sodergren E.,
RA   Song X.-Z., Steffen D., Lovering R.C., Wheeler D.A., Worley K.C., Yuan Y.,
RA   Zhang Z., Adams C.Q., Ansari-Lari M.A., Ayele M., Brown M.J., Chen G.,
RA   Chen Z., Clerc-Blankenburg K.P., Davis C., Delgado O., Dinh H.H.,
RA   Draper H., Gonzalez-Garay M.L., Havlak P., Jackson L.R., Jacob L.S.,
RA   Kelly S.H., Li L., Li Z., Liu J., Liu W., Lu J., Maheshwari M.,
RA   Nguyen B.-V., Okwuonu G.O., Pasternak S., Perez L.M., Plopper F.J.H.,
RA   Santibanez J., Shen H., Tabor P.E., Verduzco D., Waldron L., Wang Q.,
RA   Williams G.A., Zhang J., Zhou J., Allen C.C., Amin A.G., Anyalebechi V.,
RA   Bailey M., Barbaria J.A., Bimage K.E., Bryant N.P., Burch P.E.,
RA   Burkett C.E., Burrell K.L., Calderon E., Cardenas V., Carter K., Casias K.,
RA   Cavazos I., Cavazos S.R., Ceasar H., Chacko J., Chan S.N., Chavez D.,
RA   Christopoulos C., Chu J., Cockrell R., Cox C.D., Dang M., Dathorne S.R.,
RA   David R., Davis C.M., Davy-Carroll L., Deshazo D.R., Donlin J.E.,
RA   D'Souza L., Eaves K.A., Egan A., Emery-Cohen A.J., Escotto M., Flagg N.,
RA   Forbes L.D., Gabisi A.M., Garza M., Hamilton C., Henderson N.,
RA   Hernandez O., Hines S., Hogues M.E., Huang M., Idlebird D.G., Johnson R.,
RA   Jolivet A., Jones S., Kagan R., King L.M., Leal B., Lebow H., Lee S.,
RA   LeVan J.M., Lewis L.C., London P., Lorensuhewa L.M., Loulseged H.,
RA   Lovett D.A., Lucier A., Lucier R.L., Ma J., Madu R.C., Mapua P.,
RA   Martindale A.D., Martinez E., Massey E., Mawhiney S., Meador M.G.,
RA   Mendez S., Mercado C., Mercado I.C., Merritt C.E., Miner Z.L., Minja E.,
RA   Mitchell T., Mohabbat F., Mohabbat K., Montgomery B., Moore N., Morris S.,
RA   Munidasa M., Ngo R.N., Nguyen N.B., Nickerson E., Nwaokelemeh O.O.,
RA   Nwokenkwo S., Obregon M., Oguh M., Oragunye N., Oviedo R.J., Parish B.J.,
RA   Parker D.N., Parrish J., Parks K.L., Paul H.A., Payton B.A., Perez A.,
RA   Perrin W., Pickens A., Primus E.L., Pu L.-L., Puazo M., Quiles M.M.,
RA   Quiroz J.B., Rabata D., Reeves K., Ruiz S.J., Shao H., Sisson I.,
RA   Sonaike T., Sorelle R.P., Sutton A.E., Svatek A.F., Svetz L.A.,
RA   Tamerisa K.S., Taylor T.R., Teague B., Thomas N., Thorn R.D., Trejos Z.Y.,
RA   Trevino B.K., Ukegbu O.N., Urban J.B., Vasquez L.I., Vera V.A.,
RA   Villasana D.M., Wang L., Ward-Moore S., Warren J.T., Wei X., White F.,
RA   Williamson A.L., Wleczyk R., Wooden H.S., Wooden S.H., Yen J., Yoon L.,
RA   Yoon V., Zorrilla S.E., Nelson D., Kucherlapati R., Weinstock G.,
RA   Gibbs R.A.;
RT   "The finished DNA sequence of human chromosome 12.";
RL   Nature 440:346-351(2006).
RN   [11]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [12]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Muscle;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [13]
RP   PROTEIN SEQUENCE OF 41-57 (ISOFORM 1).
RC   TISSUE=Urine;
RX   PubMed=8015639; DOI=10.1159/000187851;
RA   Suzuki J., Tomizawa S., Arai H., Seki Y., Maruyama K., Kuroume T.;
RT   "Purification of two types of TNF inhibitors in the urine of the patient
RT   with chronic glomerulonephritis.";
RL   Nephron 66:386-390(1994).
RN   [14]
RP   PROTEIN SEQUENCE OF 41-45 (ISOFORM 1).
RX   PubMed=2153136; DOI=10.1016/s0021-9258(19)40049-5;
RA   Engelmann H., Novick D., Wallach D.;
RT   "Two tumor necrosis factor-binding proteins purified from human urine.
RT   Evidence for immunological cross-reactivity with cell surface tumor
RT   necrosis factor receptors.";
RL   J. Biol. Chem. 265:1531-1536(1990).
RN   [15]
RP   INTERACTION WITH MADD.
RX   PubMed=9115275; DOI=10.1074/jbc.272.18.12069;
RA   Schievella A.R., Chen J.H., Graham J.R., Lin L.-L.;
RT   "MADD, a novel death domain protein that interacts with the type 1 tumor
RT   necrosis factor receptor and activates mitogen-activated protein kinase.";
RL   J. Biol. Chem. 272:12069-12075(1997).
RN   [16]
RP   INTERACTION WITH HCV CORE PROTEIN (MICROBIAL INFECTION).
RX   PubMed=9557650; DOI=10.1128/jvi.72.5.3691-3697.1998;
RA   Zhu N., Khoshnan A., Schneider R., Matsumoto M., Dennert G., Ware C.F.,
RA   Lai M.M.C.;
RT   "Hepatitis C virus core protein binds to the cytoplasmic domain of tumor
RT   necrosis factor (TNF) receptor 1 and enhances TNF-induced apoptosis.";
RL   J. Virol. 72:3691-3697(1998).
RN   [17]
RP   INTERACTION WITH RIPK1 AND SQSTM1.
RX   PubMed=10356400; DOI=10.1093/emboj/18.11.3044;
RA   Sanz L., Sanchez P., Lallena M.-J., Diaz-Meco M.T., Moscat J.;
RT   "The interaction of p62 with RIP links the atypical PKCs to NF-kappaB
RT   activation.";
RL   EMBO J. 18:3044-3053(1999).
RN   [18]
RP   INTERACTION WITH FEM1B.
RX   PubMed=10542291; DOI=10.1074/jbc.274.45.32461;
RA   Chan S.-L., Tan K.-O., Zhang L., Yee K.S.Y., Ronca F., Chan M.-Y., Yu V.C.;
RT   "F1Aalpha, a death receptor-binding protein homologous to the
RT   Caenorhabditis elegans sex-determining protein, FEM-1, is a caspase
RT   substrate that mediates apoptosis.";
RL   J. Biol. Chem. 274:32461-32468(1999).
RN   [19]
RP   INTERACTION WITH GRB2.
RX   PubMed=10359574; DOI=10.1084/jem.189.11.1707;
RA   Hildt E., Oess S.;
RT   "Identification of Grb2 as a novel binding partner of tumor necrosis factor
RT   (TNF) receptor I.";
RL   J. Exp. Med. 189:1707-1714(1999).
RN   [20]
RP   INTERACTION WITH BAG4.
RX   PubMed=9915703; DOI=10.1126/science.283.5401.543;
RA   Jiang Y., Woronicz J.D., Liu W., Goeddel D.V.;
RT   "Prevention of constitutive TNF receptor 1 signaling by silencer of death
RT   domains.";
RL   Science 283:543-546(1999).
RN   [21]
RP   INTERACTION WITH BABAM2.
RX   PubMed=15465831; DOI=10.1074/jbc.m408678200;
RA   Li Q., Ching A.K.-K., Chan B.C.-L., Chow S.K.-Y., Lim P.-L., Ho T.C.-Y.,
RA   Ip W.-K., Wong C.-K., Lam C.W.-K., Lee K.K.-H., Chan J.Y.-H., Chui Y.-L.;
RT   "A death receptor-associated anti-apoptotic protein, BRE, inhibits
RT   mitochondrial apoptotic pathway.";
RL   J. Biol. Chem. 279:52106-52116(2004).
RN   [22]
RP   INTERACTION WITH STAPHYLOCOCCUS AUREUS PROTEIN A (MICROBIAL INFECTION).
RX   PubMed=15247912; DOI=10.1038/nm1079;
RA   Gomez M.I., Lee A., Reddy B., Muir A., Soong G., Pitt A., Cheung A.,
RA   Prince A.;
RT   "Staphylococcus aureus protein A induces airway epithelial inflammatory
RT   responses by activating TNFR1.";
RL   Nat. Med. 10:842-848(2004).
RN   [23]
RP   INTERACTION WITH STAPHYLOCOCCUS AUREUS PROTEIN A (MICROBIAL INFECTION).
RX   PubMed=16709567; DOI=10.1074/jbc.m601956200;
RA   Gomez M.I., O'Seaghdha M., Magargee M., Foster T.J., Prince A.S.;
RT   "Staphylococcus aureus protein A activates TNFR1 signaling through
RT   conserved IgG binding domains.";
RL   J. Biol. Chem. 281:20190-20196(2006).
RN   [24]
RP   INTERACTION WITH HHV-5 PROTEIN UL138 (MICROBIAL INFECTION).
RX   PubMed=21976655; DOI=10.1128/jvi.06005-11;
RA   Le V.T., Trilling M., Hengel H.;
RT   "The cytomegaloviral protein pUL138 acts as potentiator of tumor necrosis
RT   factor (TNF) receptor 1 surface density to enhance ULb'-encoded modulation
RT   of TNF-alpha signaling.";
RL   J. Virol. 85:13260-13270(2011).
RN   [25]
RP   INVOLVEMENT IN MS5, SUBCELLULAR LOCATION, AND ALTERNATIVE SPLICING (ISOFORM
RP   4).
RX   PubMed=22801493; DOI=10.1038/nature11307;
RA   Gregory A.P., Dendrou C.A., Attfield K.E., Haghikia A., Xifara D.K.,
RA   Butter F., Poschmann G., Kaur G., Lambert L., Leach O.A., Promel S.,
RA   Punwani D., Felce J.H., Davis S.J., Gold R., Nielsen F.C., Siegel R.M.,
RA   Mann M., Bell J.I., McVean G., Fugger L.;
RT   "TNF receptor 1 genetic risk mirrors outcome of anti-TNF therapy in
RT   multiple sclerosis.";
RL   Nature 488:508-511(2012).
RN   [26]
RP   GLYCOSYLATION AT ARG-376 (MICROBIAL INFECTION).
RX   PubMed=23955153; DOI=10.1038/nature12436;
RA   Li S., Zhang L., Yao Q., Li L., Dong N., Rong J., Gao W., Ding X., Sun L.,
RA   Chen X., Chen S., Shao F.;
RT   "Pathogen blocks host death receptor signalling by arginine GlcNAcylation
RT   of death domains.";
RL   Nature 501:242-246(2013).
RN   [27]
RP   INTERACTION WITH SH3RF2; RIPK1 AND TRADD.
RX   PubMed=24130170; DOI=10.1093/carcin/bgt338;
RA   Kim T.W., Kang Y.K., Park Z.Y., Kim Y.H., Hong S.W., Oh S.J., Sohn H.A.,
RA   Yang S.J., Jang Y.J., Lee D.C., Kim S.Y., Yoo H.S., Kim E., Yeom Y.I.,
RA   Park K.C.;
RT   "SH3RF2 functions as an oncogene by mediating PAK4 protein stability.";
RL   Carcinogenesis 35:624-634(2014).
RN   [28]
RP   INTERACTION WITH PGLYRP1.
RX   PubMed=26183779; DOI=10.1074/jbc.m115.639732;
RA   Yashin D.V., Ivanova O.K., Soshnikova N.V., Sheludchenkov A.A.,
RA   Romanova E.A., Dukhanina E.A., Tonevitsky A.G., Gnuchev N.V., Gabibov A.G.,
RA   Georgiev G.P., Sashchenko L.P.;
RT   "Tag7 (PGLYRP1) in Complex with Hsp70 Induces Alternative Cytotoxic
RT   Processes in Tumor Cells via TNFR1 Receptor.";
RL   J. Biol. Chem. 290:21724-21731(2015).
RN   [29]
RP   INTERACTION WITH MUMPS VIRUS PROTEIN SH (MICROBIAL INFECTION).
RX   PubMed=28659487; DOI=10.1128/jvi.01037-17;
RA   Franz S., Rennert P., Woznik M., Gruetzke J., Luedde A., Arriero Pais E.M.,
RA   Finsterbusch T., Geyer H., Mankertz A., Friedrich N.;
RT   "Mumps virus SH protein inhibits NF-kappaB activation by interacting with
RT   tumor necrosis factor receptor 1, interleukin-1 receptor 1, and Toll-like
RT   receptor 3 complexes.";
RL   J. Virol. 91:0-0(2017).
RN   [30]
RP   GLYCOSYLATION AT ARG-376 (MICROBIAL INFECTION), AND MUTAGENESIS OF ARG-376.
RX   PubMed=30979585; DOI=10.1016/j.molcel.2019.03.028;
RA   Ding J., Pan X., Du L., Yao Q., Xue J., Yao H., Wang D.C., Li S., Shao F.;
RT   "Structural and functional insights into host death domains inactivation by
RT   the bacterial arginine GlcNAcyltransferase effector.";
RL   Mol. Cell 74:922-935(2019).
RN   [31]
RP   GLYCOSYLATION (MICROBIAL INFECTION).
RX   PubMed=32766249; DOI=10.3389/fcell.2020.00641;
RA   Xue J., Hu S., Huang Y., Zhang Q., Yi X., Pan X., Li S.;
RT   "Arg-GlcNAcylation on TRADD by NleB and SseK1 is crucial for bacterial
RT   pathogenesis.";
RL   Front. Cell Dev. Biol. 8:641-641(2020).
RN   [32]
RP   X-RAY CRYSTALLOGRAPHY (2.85 ANGSTROMS) OF 30-211 IN COMPLEX WITH TNFB.
RX   PubMed=8387891; DOI=10.1016/0092-8674(93)90132-a;
RA   Banner D.W., D'Arcy A., Janes W., Gentz R., Schoenfeld H.-J., Broger C.,
RA   Loetscher H., Lesslauer W.;
RT   "Crystal structure of the soluble human 55 kd TNF receptor-human TNF beta
RT   complex: implications for TNF receptor activation.";
RL   Cell 73:431-445(1993).
RN   [33]
RP   X-RAY CRYSTALLOGRAPHY (1.85 ANGSTROMS) OF 41-202.
RX   PubMed=8939750; DOI=10.1016/s0969-2126(96)00134-7;
RA   Naismith J.H., Devine T.Q., Khono H., Sprang S.R.;
RT   "Structures of the extracellular domain of the type I tumor necrosis factor
RT   receptor.";
RL   Structure 4:1251-1262(1996).
RN   [34]
RP   VARIANTS FPF ARG-59; TYR-62; MET-79; PHE-81; ARG-117 AND TYR-117.
RX   PubMed=10199409; DOI=10.1016/s0092-8674(00)80721-7;
RA   McDermott M.F., Aksentijevich I., Galon J., McDermott E.M.,
RA   Ogunkolade B.W., Centola M., Mansfield E., Gadina M., Karenko L.,
RA   Pettersson T., McCarthy J., Frucht D.M., Aringer M., Torosyan Y.,
RA   Teppo A.-M., Wilson M., Karaarslan H.M., Wan Y., Todd I., Wood G.,
RA   Schlimgen R., Kumarajeewa T.R., Cooper S.M., Vella J.P., Amos C.I.,
RA   Mulley J., Quane K.A., Molloy M.G., Rnaki A., Powell R.J., Hitman G.A.,
RA   O'Shea J., Kastner D.L.;
RT   "Germline mutations in the extracellular domains of the 55 kDa TNF
RT   receptor, TNFR1, define a family of dominantly inherited autoinflammatory
RT   syndromes.";
RL   Cell 97:133-144(1999).
RN   [35]
RP   VARIANT FPF SER-59.
RX   PubMed=10902757;
RX   DOI=10.1002/1529-0131(200007)43:7<1535::aid-anr18>3.0.co;2-c;
RA   Dode C., Papo T., Fieschi C., Pecheux C., Dion E., Picard F., Godeau P.,
RA   Bienvenu J., Piette J.-C., Delpech M., Grateau G.;
RT   "A novel missense mutation (C30S) in the gene encoding tumor necrosis
RT   factor receptor 1 linked to autosomal-dominant recurrent fever with
RT   localized myositis in a French family.";
RL   Arthritis Rheum. 43:1535-1542(2000).
RN   [36]
RP   VARIANTS FPF GLN-51; SER-59; GLY-62; LEU-75; GLY-115 AND GLN-121.
RX   PubMed=11443543; DOI=10.1086/321976;
RA   Aksentijevich I., Galon J., Soares M., Mansfield E., Hull K., Oh H.-H.,
RA   Goldbach-Mansky R., Dean J., Athreya B., Reginato A.J., Henrickson M.,
RA   Pons-Estel B., O'Shea J.J., Kastner D.L.;
RT   "The tumor-necrosis-factor receptor-associated periodic syndrome: new
RT   mutations in TNFRSF1A, ancestral origins, genotype-phenotype studies, and
RT   evidence for further genetic heterogeneity of periodic fevers.";
RL   Am. J. Hum. Genet. 69:301-314(2001).
RN   [37]
RP   VARIANTS FPF SER-99 AND PRO-121.
RX   PubMed=13130484; DOI=10.1002/art.11215;
RA   Aganna E., Hammond L., Hawkins P.N., Aldea A., McKee S.A.,
RA   Ploos van Amstel H.K., Mischung C., Kusuhara K., Saulsbury F.T.,
RA   Lachmann H.J., Bybee A., McDermott E.M., La Regina M., Arostegui J.I.,
RA   Campistol J.M., Worthington S., High K.P., Molloy M.G., Baker N.,
RA   Bidwell J.L., Castaner J.L., Whiteford M.L., Janssens-Korpola P.L.,
RA   Manna R., Powell R.J., Woo P., Solis P., Minden K., Frenkel J., Yague J.,
RA   Mirakian R.M., Hitman G.A., McDermott M.F.;
RT   "Heterogeneity among patients with tumor necrosis factor receptor-
RT   associated periodic syndrome phenotypes.";
RL   Arthritis Rheum. 48:2632-2644(2003).
RN   [38]
RP   VARIANT FPF SER-99.
RX   PubMed=14610673; DOI=10.1007/s00431-003-1338-0;
RA   Kusuhara K., Nomura A., Nakao F., Hara T.;
RT   "Tumour necrosis factor receptor-associated periodic syndrome with a novel
RT   mutation in the TNFRSF1A gene in a Japanese family.";
RL   Eur. J. Pediatr. 163:30-32(2004).
CC   -!- FUNCTION: Receptor for TNFSF2/TNF and homotrimeric TNFSF1/lymphotoxin-
CC       alpha. The adapter molecule FADD recruits caspase-8 to the activated
CC       receptor. The resulting death-inducing signaling complex (DISC)
CC       performs caspase-8 proteolytic activation which initiates the
CC       subsequent cascade of caspases (aspartate-specific cysteine proteases)
CC       mediating apoptosis. Contributes to the induction of non-cytocidal TNF
CC       effects including anti-viral state and activation of the acid
CC       sphingomyelinase.
CC   -!- SUBUNIT: Binding of TNF to the extracellular domain leads to
CC       homotrimerization. The aggregated death domains provide a novel
CC       molecular interface that interacts specifically with the death domain
CC       of TRADD. Various TRADD-interacting proteins such as TRAFS, RIPK1 and
CC       possibly FADD, are recruited to the complex by their association with
CC       TRADD. This complex activates at least two distinct signaling cascades,
CC       apoptosis and NF-kappa-B signaling. Interacts with BAG4, BABAM2, FEM1B,
CC       GRB2, SQSTM1 and TRPC4AP (PubMed:10356400, PubMed:10359574,
CC       PubMed:10542291, PubMed:15465831, PubMed:8387891, PubMed:9915703).
CC       Interacts directly with NOL3 (via CARD domain); inhibits TNF-signaling
CC       pathway (By similarity). Interacts with SH3RF2, TRADD and RIPK1. SH3RF2
CC       facilitates the recruitment of RIPK1 and TRADD to TNFRSF1A in a TNF-
CC       dependent process (PubMed:24130170). Interacts with PGLYRP1; this
CC       interaction is important for cell death induction (PubMed:26183779).
CC       Interacts (via death domain) with MADD (via death domain)
CC       (PubMed:9115275). {ECO:0000250|UniProtKB:P25118,
CC       ECO:0000269|PubMed:10356400, ECO:0000269|PubMed:10359574,
CC       ECO:0000269|PubMed:10542291, ECO:0000269|PubMed:15465831,
CC       ECO:0000269|PubMed:24130170, ECO:0000269|PubMed:26183779,
CC       ECO:0000269|PubMed:8387891, ECO:0000269|PubMed:9115275,
CC       ECO:0000269|PubMed:9915703}.
CC   -!- SUBUNIT: (Microbial infection) Interacts with mumps virus protein SH;
CC       this interaction inhibits downstream NF-kappa-B pathway activation.
CC       {ECO:0000269|PubMed:28659487}.
CC   -!- SUBUNIT: (Microbial infection) Interacts with HCV core protein.
CC       {ECO:0000269|PubMed:9557650}.
CC   -!- SUBUNIT: (Microbial infection) Interacts with human
CC       cytomegalovirus/HHV-5 protein UL138. {ECO:0000269|PubMed:21976655}.
CC   -!- SUBUNIT: (Microbial infection) Interacts with host TNFRSF1A; this
CC       interaction leads to the stimulation of both surface expression and
CC       shedding of TNFRSF1A. {ECO:0000269|PubMed:15247912,
CC       ECO:0000269|PubMed:16709567}.
CC   -!- INTERACTION:
CC       P19438; P28799: GRN; NbExp=4; IntAct=EBI-299451, EBI-747754;
CC       P19438; Q7Z3U7: MON2; NbExp=2; IntAct=EBI-299451, EBI-358882;
CC       P19438; Q969G6: RFK; NbExp=4; IntAct=EBI-299451, EBI-716872;
CC       P19438; Q13546: RIPK1; NbExp=7; IntAct=EBI-299451, EBI-358507;
CC       P19438; P01375: TNF; NbExp=32; IntAct=EBI-299451, EBI-359977;
CC       P19438; P19438: TNFRSF1A; NbExp=3; IntAct=EBI-299451, EBI-299451;
CC       P19438; Q15628: TRADD; NbExp=16; IntAct=EBI-299451, EBI-359215;
CC       P19438; P0CG47: UBB; NbExp=2; IntAct=EBI-299451, EBI-413034;
CC       P19438-1; Q969G6: RFK; NbExp=2; IntAct=EBI-15795644, EBI-716872;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:22801493};
CC       Single-pass type I membrane protein {ECO:0000269|PubMed:22801493}.
CC       Golgi apparatus membrane {ECO:0000269|PubMed:22801493}; Single-pass
CC       type I membrane protein {ECO:0000269|PubMed:22801493}. Secreted
CC       {ECO:0000269|PubMed:22801493}. Note=A secreted form is produced through
CC       proteolytic processing.
CC   -!- SUBCELLULAR LOCATION: [Isoform 4]: Secreted. Note=Lacks a Golgi-
CC       retention motif, is not membrane bound and therefore is secreted.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=5;
CC       Name=1; Synonyms=FL-TNFR1;
CC         IsoId=P19438-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P19438-2; Sequence=VSP_037153;
CC       Name=4; Synonyms=Delta6-TNFR1;
CC         IsoId=P19438-4; Sequence=VSP_044949;
CC       Name=3;
CC         IsoId=P19438-3; Sequence=VSP_037154;
CC       Name=5;
CC         IsoId=P19438-5; Sequence=VSP_047613, VSP_047614;
CC   -!- DOMAIN: The domain that induces A-SMASE is probably identical to the
CC       death domain. The N-SMASE activation domain (NSD) is both necessary and
CC       sufficient for activation of N-SMASE.
CC   -!- DOMAIN: Both the cytoplasmic membrane-proximal region and the C-
CC       terminal region containing the death domain are involved in the
CC       interaction with TRPC4AP. {ECO:0000250}.
CC   -!- PTM: The soluble form is produced from the membrane form by proteolytic
CC       processing.
CC   -!- PTM: (Microbial infection) Glycosylated at Arg-376 by enteropathogenic
CC       E.coli protein NleB1 and S.typhimurium protein Ssek3: arginine
CC       GlcNAcylation prevents homotypic/heterotypic death domain interactions.
CC       {ECO:0000269|PubMed:32766249, ECO:0000305|PubMed:23955153}.
CC   -!- DISEASE: Periodic fever, familial, autosomal dominant (FPF)
CC       [MIM:142680]: A hereditary periodic fever syndrome characterized by
CC       recurrent fever, abdominal pain, localized tender skin lesions and
CC       myalgia. Reactive amyloidosis is the main complication and occurs in
CC       25% of cases. {ECO:0000269|PubMed:10199409,
CC       ECO:0000269|PubMed:10902757, ECO:0000269|PubMed:11443543,
CC       ECO:0000269|PubMed:13130484, ECO:0000269|PubMed:14610673}. Note=The
CC       disease is caused by variants affecting the gene represented in this
CC       entry.
CC   -!- DISEASE: Multiple sclerosis 5 (MS5) [MIM:614810]: A multifactorial,
CC       inflammatory, demyelinating disease of the central nervous system.
CC       Sclerotic lesions are characterized by perivascular infiltration of
CC       monocytes and lymphocytes and appear as indurated areas in pathologic
CC       specimens (sclerosis in plaques). The pathological mechanism is
CC       regarded as an autoimmune attack of the myelin sheath, mediated by both
CC       cellular and humoral immunity. Clinical manifestations include visual
CC       loss, extra-ocular movement disorders, paresthesias, loss of sensation,
CC       weakness, dysarthria, spasticity, ataxia and bladder dysfunction.
CC       Genetic and environmental factors influence susceptibility to the
CC       disease. {ECO:0000269|PubMed:22801493}. Note=Disease susceptibility is
CC       associated with variants affecting the gene represented in this entry.
CC       An intronic mutation affecting alternative splicing and skipping of
CC       exon 6 directs increased expression of isoform 4 a transcript encoding
CC       a C-terminally truncated protein which is secreted and may function as
CC       a TNF antagonist.
CC   -!- MISCELLANEOUS: [Isoform 4]: Disease-associated isoform. Isoform 4
CC       splicing pattern is driven by a variation in the exon 6/intron 6
CC       boundary region that alters exon 6 splicing. Exon 6 skipping introduces
CC       a frameshift and the translation of a protein lacking the
CC       intracellular, the transmembrane and part of the extracellular domain.
CC       {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=INFEVERS; Note=Repertory of FMF and hereditary
CC       autoinflammatory disorders mutations;
CC       URL="https://infevers.umai-montpellier.fr/web/search.php?n=22";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; M58286; AAA36753.1; -; mRNA.
DR   EMBL; M33294; AAA03210.1; -; mRNA.
DR   EMBL; M63121; AAA36754.1; -; mRNA.
DR   EMBL; X55313; CAA39021.1; -; mRNA.
DR   EMBL; M60275; AAA36756.1; -; mRNA.
DR   EMBL; M75866; AAA61201.1; -; Genomic_DNA.
DR   EMBL; M75864; AAA61201.1; JOINED; Genomic_DNA.
DR   EMBL; M75865; AAA61201.1; JOINED; Genomic_DNA.
DR   EMBL; AY131997; AAM77802.1; -; Genomic_DNA.
DR   EMBL; AK056611; BAG51763.1; -; mRNA.
DR   EMBL; AK291088; BAF83777.1; -; mRNA.
DR   EMBL; AK298729; BAG60879.1; -; mRNA.
DR   EMBL; AK304517; BAG65321.1; -; mRNA.
DR   EMBL; AK315509; BAG37891.1; -; mRNA.
DR   EMBL; EU927389; ACH57451.1; -; mRNA.
DR   EMBL; AC006057; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471116; EAW88805.1; -; Genomic_DNA.
DR   EMBL; CH471116; EAW88806.1; -; Genomic_DNA.
DR   EMBL; BC010140; AAH10140.1; -; mRNA.
DR   CCDS; CCDS8542.1; -. [P19438-1]
DR   PIR; A38208; GQHUT1.
DR   RefSeq; NP_001056.1; NM_001065.4. [P19438-1]
DR   RefSeq; NP_001333020.1; NM_001346091.2. [P19438-2]
DR   RefSeq; NP_001333021.1; NM_001346092.1.
DR   PDB; 1EXT; X-ray; 1.85 A; A/B=41-201.
DR   PDB; 1FT4; X-ray; 2.90 A; A/B=41-201.
DR   PDB; 1ICH; NMR; -; A=345-455.
DR   PDB; 1NCF; X-ray; 2.25 A; A/B=41-201.
DR   PDB; 1TNR; X-ray; 2.85 A; R=44-182.
DR   PDB; 7K7A; NMR; -; A/B/C=209-238.
DR   PDB; 7KP7; X-ray; 2.65 A; D/E/F=42-184.
DR   PDB; 7KP8; X-ray; 3.15 A; E/F=43-184.
DR   PDB; 7KPB; X-ray; 3.00 A; E/F=42-184.
DR   PDB; 8P6Q; X-ray; 1.40 A; A=101-145.
DR   PDB; 8ZUI; EM; 2.56 A; D/E/F/J/K/L=30-211.
DR   PDBsum; 1EXT; -.
DR   PDBsum; 1FT4; -.
DR   PDBsum; 1ICH; -.
DR   PDBsum; 1NCF; -.
DR   PDBsum; 1TNR; -.
DR   PDBsum; 7K7A; -.
DR   PDBsum; 7KP7; -.
DR   PDBsum; 7KP8; -.
DR   PDBsum; 7KPB; -.
DR   PDBsum; 8P6Q; -.
DR   PDBsum; 8ZUI; -.
DR   AlphaFoldDB; P19438; -.
DR   BMRB; P19438; -.
DR   EMDB; EMD-60484; -.
DR   EMDB; EMD-60489; -.
DR   EMDB; EMD-60490; -.
DR   EMDB; EMD-60491; -.
DR   EMDB; EMD-60494; -.
DR   EMDB; EMD-60497; -.
DR   EMDB; EMD-60549; -.
DR   SMR; P19438; -.
DR   BioGRID; 112986; 209.
DR   ComplexPortal; CPX-25723; sTNF-TNR1A receptor-ligand core complex, BIRC3 variant.
DR   ComplexPortal; CPX-25726; mTNF-TNR1A receptor-ligand core complex, BIRC3 variant.
DR   ComplexPortal; CPX-8828; sTNF-TNR1A receptor-ligand core complex, BIRC2 variant.
DR   ComplexPortal; CPX-8932; mTNF-TNR1A receptor-ligand core complex, BIRC2 variant.
DR   ComplexPortal; CPX-8945; Lymphotoxin-alpha-TNFRSF1A receptor complex.
DR   CORUM; P19438; -.
DR   DIP; DIP-407N; -.
DR   FunCoup; P19438; 1321.
DR   IntAct; P19438; 179.
DR   MINT; P19438; -.
DR   STRING; 9606.ENSP00000162749; -.
DR   BindingDB; P19438; -.
DR   ChEMBL; CHEMBL3378; -.
DR   DrugBank; DB03507; 6-[3-(4-Morpholinyl)Propyl]-2-(3-Nitrophenyl)-5-Thioxo-5,6,-Dihydro-7h-Thienol[2',3':4,5]Pyrrolo[1,2-C]Imidazol-7-One.
DR   DrugBank; DB11626; Tasonermin.
DR   DrugCentral; P19438; -.
DR   GlyCosmos; P19438; 4 sites, No reported glycans.
DR   GlyGen; P19438; 4 sites, 2 N-linked glycans (1 site).
DR   iPTMnet; P19438; -.
DR   PhosphoSitePlus; P19438; -.
DR   SwissPalm; P19438; -.
DR   BioMuta; TNFRSF1A; -.
DR   DMDM; 135959; -.
DR   jPOST; P19438; -.
DR   MassIVE; P19438; -.
DR   PaxDb; 9606-ENSP00000162749; -.
DR   PeptideAtlas; P19438; -.
DR   ProteomicsDB; 53659; -. [P19438-1]
DR   ProteomicsDB; 53660; -. [P19438-2]
DR   ProteomicsDB; 53661; -. [P19438-3]
DR   ProteomicsDB; 5939; -.
DR   ABCD; P19438; 189 sequenced antibodies.
DR   Antibodypedia; 1320; 1505 antibodies from 50 providers.
DR   DNASU; 7132; -.
DR   Ensembl; ENST00000162749.7; ENSP00000162749.2; ENSG00000067182.10. [P19438-1]
DR   Ensembl; ENST00000437813.8; ENSP00000513672.1; ENSG00000067182.10. [P19438-5]
DR   Ensembl; ENST00000698339.1; ENSP00000513670.1; ENSG00000067182.10. [P19438-5]
DR   Ensembl; ENST00000698340.1; ENSP00000513671.1; ENSG00000067182.10. [P19438-4]
DR   GeneID; 7132; -.
DR   KEGG; hsa:7132; -.
DR   MANE-Select; ENST00000162749.7; ENSP00000162749.2; NM_001065.4; NP_001056.1.
DR   UCSC; uc001qnu.4; human. [P19438-1]
DR   AGR; HGNC:11916; -.
DR   ClinPGx; PA36609; -.
DR   CTD; 7132; -.
DR   DisGeNET; 7132; -.
DR   GeneCards; TNFRSF1A; -.
DR   GeneReviews; TNFRSF1A; -.
DR   HGNC; HGNC:11916; TNFRSF1A.
DR   HPA; ENSG00000067182; Low tissue specificity.
DR   MalaCards; TNFRSF1A; -.
DR   MIM; 142680; phenotype.
DR   MIM; 191190; gene.
DR   MIM; 614810; phenotype.
DR   OpenTargets; ENSG00000067182; -.
DR   Orphanet; 329967; Intermittent hydrarthrosis.
DR   Orphanet; 32960; Tumor necrosis factor receptor 1 associated periodic syndrome.
DR   VEuPathDB; HostDB:ENSG00000067182; -.
DR   eggNOG; ENOG502S050; Eukaryota.
DR   GeneTree; ENSGT00940000159540; -.
DR   HOGENOM; CLU_050864_0_0_1; -.
DR   InParanoid; P19438; -.
DR   OMA; IVETPCT; -.
DR   OrthoDB; 9408020at2759; -.
DR   PAN-GO; P19438; 6 GO annotations based on evolutionary models.
DR   PhylomeDB; P19438; -.
DR   PathwayCommons; P19438; -.
DR   Reactome; R-HSA-5357786; TNFR1-induced proapoptotic signaling.
DR   Reactome; R-HSA-5357905; Regulation of TNFR1 signaling.
DR   Reactome; R-HSA-5357956; TNFR1-induced NF-kappa-B signaling pathway.
DR   Reactome; R-HSA-5626978; TNFR1-mediated ceramide production.
DR   Reactome; R-HSA-5669034; TNFs bind their physiological receptors.
DR   Reactome; R-HSA-6783783; Interleukin-10 signaling.
DR   Reactome; R-HSA-75893; TNF signaling.
DR   SignaLink; P19438; -.
DR   SIGNOR; P19438; -.
DR   Agora; ENSG00000067182; Agora Nominated Target for Alzheimer's Disease.
DR   BioGRID-ORCS; 7132; 29 hits in 1171 CRISPR screens.
DR   ChiTaRS; TNFRSF1A; human.
DR   EvolutionaryTrace; P19438; -.
DR   GeneWiki; TNFRSF1A; -.
DR   GenomeRNAi; 7132; -.
DR   Pharos; P19438; Tchem.
DR   PRO; PR:P19438; -.
DR   Proteomes; UP000005640; Chromosome 12.
DR   RNAct; P19438; protein.
DR   Bgee; ENSG00000067182; Expressed in tendon of biceps brachii and 200 other cell types or tissues.
DR   ExpressionAtlas; P19438; baseline and differential.
DR   GO; GO:0009986; C:cell surface; IDA:UniProt.
DR   GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR   GO; GO:0005615; C:extracellular space; IDA:BHF-UCL.
DR   GO; GO:0000139; C:Golgi membrane; IDA:UniProtKB.
DR   GO; GO:0016020; C:membrane; TAS:ARUK-UCL.
DR   GO; GO:0045121; C:membrane raft; IDA:BHF-UCL.
DR   GO; GO:0005886; C:plasma membrane; TAS:UniProt.
DR   GO; GO:0043235; C:receptor complex; IDA:MGI.
DR   GO; GO:0002947; C:tumor necrosis factor receptor superfamily complex; TAS:ARUK-UCL.
DR   GO; GO:0038023; F:signaling receptor activity; ISS:UniProt.
DR   GO; GO:0043120; F:tumor necrosis factor binding; IPI:ARUK-UCL.
DR   GO; GO:0005031; F:tumor necrosis factor receptor activity; IDA:UniProt.
DR   GO; GO:0003176; P:aortic valve development; ISS:BHF-UCL.
DR   GO; GO:0007249; P:canonical NF-kappaB signal transduction; IEA:Ensembl.
DR   GO; GO:0007259; P:cell surface receptor signaling pathway via JAK-STAT; IMP:BHF-UCL.
DR   GO; GO:0071260; P:cellular response to mechanical stimulus; IEP:UniProtKB.
DR   GO; GO:0019221; P:cytokine-mediated signaling pathway; ISS:UniProtKB.
DR   GO; GO:0042742; P:defense response to bacterium; IEA:Ensembl.
DR   GO; GO:0008625; P:extrinsic apoptotic signaling pathway via death domain receptors; TAS:BHF-UCL.
DR   GO; GO:0006954; P:inflammatory response; ISS:UniProtKB.
DR   GO; GO:0008630; P:intrinsic apoptotic signaling pathway in response to DNA damage; IEA:Ensembl.
DR   GO; GO:0043124; P:negative regulation of canonical NF-kappaB signal transduction; IEA:Ensembl.
DR   GO; GO:0010614; P:negative regulation of cardiac muscle hypertrophy; IEA:Ensembl.
DR   GO; GO:0003332; P:negative regulation of extracellular matrix constituent secretion; ISS:BHF-UCL.
DR   GO; GO:0050728; P:negative regulation of inflammatory response; IMP:BHF-UCL.
DR   GO; GO:0034250; P:positive regulation of amide metabolic process; IEA:Ensembl.
DR   GO; GO:1902339; P:positive regulation of apoptotic process involved in morphogenesis; ISS:BHF-UCL.
DR   GO; GO:0043123; P:positive regulation of canonical NF-kappaB signal transduction; IEP:UniProtKB.
DR   GO; GO:1900119; P:positive regulation of execution phase of apoptosis; IEA:Ensembl.
DR   GO; GO:0050729; P:positive regulation of inflammatory response; ISS:UniProtKB.
DR   GO; GO:0045834; P:positive regulation of lipid metabolic process; IEA:Ensembl.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IMP:BHF-UCL.
DR   GO; GO:0006693; P:prostaglandin metabolic process; IEA:InterPro.
DR   GO; GO:0072659; P:protein localization to plasma membrane; IMP:UniProtKB.
DR   GO; GO:0000209; P:protein polyubiquitination; IEA:Ensembl.
DR   GO; GO:0003177; P:pulmonary valve development; ISS:BHF-UCL.
DR   GO; GO:1903140; P:regulation of establishment of endothelial barrier; IMP:UniProtKB.
DR   GO; GO:1905038; P:regulation of membrane lipid metabolic process; IEA:Ensembl.
DR   GO; GO:0010803; P:regulation of tumor necrosis factor-mediated signaling pathway; IEA:Ensembl.
DR   GO; GO:0006366; P:transcription by RNA polymerase II; IEA:Ensembl.
DR   GO; GO:0033209; P:tumor necrosis factor-mediated signaling pathway; IMP:UniProtKB.
DR   CDD; cd08313; Death_TNFR1; 1.
DR   CDD; cd10576; TNFRSF1A; 1.
DR   FunFam; 1.10.533.10:FF:000044; Tumor necrosis factor receptor superfamily member 1A; 1.
DR   FunFam; 2.10.50.10:FF:000020; Tumor necrosis factor receptor superfamily member 1A; 1.
DR   FunFam; 2.10.50.10:FF:000025; Tumor necrosis factor receptor superfamily member 1A; 1.
DR   Gene3D; 1.10.533.10; Death Domain, Fas; 1.
DR   Gene3D; 2.10.50.10; Tumor Necrosis Factor Receptor, subunit A, domain 2; 2.
DR   InterPro; IPR011029; DEATH-like_dom_sf.
DR   InterPro; IPR000488; Death_dom.
DR   InterPro; IPR001368; TNFR/NGFR_Cys_rich_reg.
DR   InterPro; IPR020419; TNFR_1A.
DR   InterPro; IPR052493; TNFRSF1A.
DR   InterPro; IPR033994; TNFRSF1A_death.
DR   InterPro; IPR033993; TNFRSF1A_N.
DR   PANTHER; PTHR46861; TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY MEMBER 1A; 1.
DR   PANTHER; PTHR46861:SF1; TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY MEMBER 1A; 1.
DR   Pfam; PF00531; Death; 1.
DR   Pfam; PF00020; TNFR_c6; 2.
DR   PRINTS; PR01918; TNFACTORR1A.
DR   SMART; SM00005; DEATH; 1.
DR   SMART; SM00208; TNFR; 4.
DR   SUPFAM; SSF47986; DEATH domain; 1.
DR   SUPFAM; SSF57586; TNF receptor-like; 3.
DR   PROSITE; PS50017; DEATH_DOMAIN; 1.
DR   PROSITE; PS00652; TNFR_NGFR_1; 3.
DR   PROSITE; PS50050; TNFR_NGFR_2; 3.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Amyloidosis; Apoptosis; Cell membrane;
KW   Cleavage on pair of basic residues; Direct protein sequencing;
KW   Disease variant; Disulfide bond; Glycoprotein; Golgi apparatus;
KW   Host-virus interaction; Membrane; Proteomics identification; Receptor;
KW   Reference proteome; Repeat; Secreted; Signal; Transmembrane;
KW   Transmembrane helix.
FT   SIGNAL          1..29
FT                   /evidence="ECO:0000269|PubMed:2158862"
FT   CHAIN           30..455
FT                   /note="Tumor necrosis factor receptor superfamily member
FT                   1A, membrane form"
FT                   /id="PRO_0000034543"
FT   CHAIN           41..201
FT                   /note="Tumor necrosis factor-binding protein 1"
FT                   /id="PRO_0000034544"
FT   TOPO_DOM        30..211
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        212..232
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        233..455
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   REPEAT          43..82
FT                   /note="TNFR-Cys 1"
FT   REPEAT          83..125
FT                   /note="TNFR-Cys 2"
FT   REPEAT          126..166
FT                   /note="TNFR-Cys 3"
FT   REPEAT          167..196
FT                   /note="TNFR-Cys 4"
FT   DOMAIN          356..441
FT                   /note="Death"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00064"
FT   REGION          254..273
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          338..348
FT                   /note="N-SMase activation domain (NSD)"
FT   CARBOHYD        54
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        145
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        151
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        376
FT                   /note="(Microbial infection) N-beta-linked (GlcNAc)
FT                   arginine"
FT                   /evidence="ECO:0000269|PubMed:30979585,
FT                   ECO:0000305|PubMed:23955153"
FT   DISULFID        44..58
FT   DISULFID        59..72
FT   DISULFID        62..81
FT   DISULFID        84..99
FT   DISULFID        102..117
FT   DISULFID        105..125
FT   DISULFID        127..143
FT   DISULFID        146..158
FT   DISULFID        149..166
FT   DISULFID        168..179
FT   DISULFID        182..195
FT   DISULFID        185..191
FT   VAR_SEQ         1..232
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_037154"
FT   VAR_SEQ         1..108
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_037153"
FT   VAR_SEQ         184..455
FT                   /note="NCKKSLECTKLCLPQIENVKGTEDSGTTVLLPLVIFFGLCLLSLLFIGLMYR
FT                   YQRWKSKLYSIVCGKSTPEKEGELEGTTTKPLAPNPSFSPTPGFTPTLGFSPVPSSTFT
FT                   SSSTYTPGDCPNFAAPRREVAPPYQGADPILATALASDPIPNPLQKWEDSAHKPQSLDT
FT                   DDPATLYAVVENVPPLRWKEFVRRLGLSDHEIDRLELQNGRCLREAQYSMLATWRRRTP
FT                   RREATLELLGRVLRDMDLLGCLEDIEEALCGPAALPPAPSLLR -> KHHSAVAPGHFL
FT                   WSLPFIPPLHWFNVSLPTVEVQALLHCLWEIDT (in isoform 4)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_044949"
FT   VAR_SEQ         184..218
FT                   /note="NCKKSLECTKLCLPQIENVKGTEDSGTTVLLPLVI -> KVLLCRPGWNAVA
FT                   RSRLTATSASQIQAILLLQPPK (in isoform 5)"
FT                   /evidence="ECO:0000303|PubMed:19906316"
FT                   /id="VSP_047613"
FT   VAR_SEQ         219..455
FT                   /note="Missing (in isoform 5)"
FT                   /evidence="ECO:0000303|PubMed:19906316"
FT                   /id="VSP_047614"
FT   VARIANT         51
FT                   /note="H -> Q (in FPF; dbSNP:rs104895254)"
FT                   /evidence="ECO:0000269|PubMed:11443543"
FT                   /id="VAR_019329"
FT   VARIANT         59
FT                   /note="C -> R (in FPF; dbSNP:rs104895217)"
FT                   /evidence="ECO:0000269|PubMed:10199409"
FT                   /id="VAR_013410"
FT   VARIANT         59
FT                   /note="C -> S (in FPF; dbSNP:rs104895223)"
FT                   /evidence="ECO:0000269|PubMed:10902757,
FT                   ECO:0000269|PubMed:11443543"
FT                   /id="VAR_019302"
FT   VARIANT         62
FT                   /note="C -> G (in FPF; dbSNP:rs104895225)"
FT                   /evidence="ECO:0000269|PubMed:11443543"
FT                   /id="VAR_019303"
FT   VARIANT         62
FT                   /note="C -> Y (in FPF; dbSNP:rs104895218)"
FT                   /evidence="ECO:0000269|PubMed:10199409"
FT                   /id="VAR_013411"
FT   VARIANT         75
FT                   /note="P -> L (in FPF; benign; dbSNP:rs4149637)"
FT                   /evidence="ECO:0000269|PubMed:11443543, ECO:0000269|Ref.7"
FT                   /id="VAR_019330"
FT   VARIANT         79
FT                   /note="T -> M (in FPF; dbSNP:rs104895219)"
FT                   /evidence="ECO:0000269|PubMed:10199409"
FT                   /id="VAR_013412"
FT   VARIANT         81
FT                   /note="C -> F (in FPF; dbSNP:rs104895220)"
FT                   /evidence="ECO:0000269|PubMed:10199409"
FT                   /id="VAR_013413"
FT   VARIANT         99
FT                   /note="C -> S (in FPF; dbSNP:rs104895228)"
FT                   /evidence="ECO:0000269|PubMed:13130484,
FT                   ECO:0000269|PubMed:14610673"
FT                   /id="VAR_019304"
FT   VARIANT         115
FT                   /note="S -> G (in FPF)"
FT                   /evidence="ECO:0000269|PubMed:11443543"
FT                   /id="VAR_019331"
FT   VARIANT         117
FT                   /note="C -> R (in FPF; dbSNP:rs104895221)"
FT                   /evidence="ECO:0000269|PubMed:10199409"
FT                   /id="VAR_013414"
FT   VARIANT         117
FT                   /note="C -> Y (in FPF; dbSNP:rs104895222)"
FT                   /evidence="ECO:0000269|PubMed:10199409"
FT                   /id="VAR_013415"
FT   VARIANT         121
FT                   /note="R -> P (in FPF; dbSNP:rs4149584)"
FT                   /evidence="ECO:0000269|PubMed:13130484"
FT                   /id="VAR_019305"
FT   VARIANT         121
FT                   /note="R -> Q (in FPF; uncertain significance;
FT                   dbSNP:rs4149584)"
FT                   /evidence="ECO:0000269|PubMed:11443543, ECO:0000269|Ref.7"
FT                   /id="VAR_019332"
FT   VARIANT         305
FT                   /note="P -> T (in dbSNP:rs1804532)"
FT                   /id="VAR_011813"
FT   MUTAGEN         376
FT                   /note="R->A: Abolished GlcNAcylation by E.coli NleB1."
FT                   /evidence="ECO:0000269|PubMed:30979585"
FT   CONFLICT        13
FT                   /note="L -> LILPQ (in Ref. 8; BAG51763)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        255
FT                   /note="K -> E (in Ref. 8; BAG37891)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        286
FT                   /note="S -> G (in Ref. 8; BAG51763)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        394
FT                   /note="R -> L (in Ref. 8; BAF83777)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        412
FT                   /note="Missing (in Ref. 5; AAA36756)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        443..446
FT                   /note="GPAA -> APP (in Ref. 5; AAA36756)"
FT                   /evidence="ECO:0000305"
FT   STRAND          48..50
FT                   /evidence="ECO:0007829|PDB:1EXT"
FT   STRAND          52..54
FT                   /evidence="ECO:0007829|PDB:1FT4"
FT   STRAND          58..60
FT                   /evidence="ECO:0007829|PDB:1EXT"
FT   STRAND          66..70
FT                   /evidence="ECO:0007829|PDB:1EXT"
FT   STRAND          73..77
FT                   /evidence="ECO:0007829|PDB:7KP8"
FT   STRAND          80..83
FT                   /evidence="ECO:0007829|PDB:1EXT"
FT   STRAND          92..94
FT                   /evidence="ECO:0007829|PDB:1EXT"
FT   HELIX           107..109
FT                   /evidence="ECO:0007829|PDB:8P6Q"
FT   STRAND          112..115
FT                   /evidence="ECO:0007829|PDB:8P6Q"
FT   STRAND          119..121
FT                   /evidence="ECO:0007829|PDB:8P6Q"
FT   STRAND          124..126
FT                   /evidence="ECO:0007829|PDB:8P6Q"
FT   STRAND          132..139
FT                   /evidence="ECO:0007829|PDB:8P6Q"
FT   STRAND          141..144
FT                   /evidence="ECO:0007829|PDB:8P6Q"
FT   STRAND          152..156
FT                   /evidence="ECO:0007829|PDB:1EXT"
FT   STRAND          160..162
FT                   /evidence="ECO:0007829|PDB:1TNR"
FT   STRAND          165..168
FT                   /evidence="ECO:0007829|PDB:1EXT"
FT   STRAND          172..175
FT                   /evidence="ECO:0007829|PDB:1EXT"
FT   STRAND          178..181
FT                   /evidence="ECO:0007829|PDB:1EXT"
FT   HELIX           182..184
FT                   /evidence="ECO:0007829|PDB:1EXT"
FT   HELIX           192..195
FT                   /evidence="ECO:0007829|PDB:1EXT"
FT   HELIX           213..236
FT                   /evidence="ECO:0007829|PDB:7K7A"
FT   HELIX           357..365
FT                   /evidence="ECO:0007829|PDB:1ICH"
FT   HELIX           371..378
FT                   /evidence="ECO:0007829|PDB:1ICH"
FT   HELIX           382..391
FT                   /evidence="ECO:0007829|PDB:1ICH"
FT   HELIX           396..410
FT                   /evidence="ECO:0007829|PDB:1ICH"
FT   HELIX           417..427
FT                   /evidence="ECO:0007829|PDB:1ICH"
FT   HELIX           431..441
FT                   /evidence="ECO:0007829|PDB:1ICH"
SQ   SEQUENCE   455 AA;  50495 MW;  4CEFBA96D03B8225 CRC64;
     MGLSTVPDLL LPLVLLELLV GIYPSGVIGL VPHLGDREKR DSVCPQGKYI HPQNNSICCT
     KCHKGTYLYN DCPGPGQDTD CRECESGSFT ASENHLRHCL SCSKCRKEMG QVEISSCTVD
     RDTVCGCRKN QYRHYWSENL FQCFNCSLCL NGTVHLSCQE KQNTVCTCHA GFFLRENECV
     SCSNCKKSLE CTKLCLPQIE NVKGTEDSGT TVLLPLVIFF GLCLLSLLFI GLMYRYQRWK
     SKLYSIVCGK STPEKEGELE GTTTKPLAPN PSFSPTPGFT PTLGFSPVPS STFTSSSTYT
     PGDCPNFAAP RREVAPPYQG ADPILATALA SDPIPNPLQK WEDSAHKPQS LDTDDPATLY
     AVVENVPPLR WKEFVRRLGL SDHEIDRLEL QNGRCLREAQ YSMLATWRRR TPRREATLEL
     LGRVLRDMDL LGCLEDIEEA LCGPAALPPA PSLLR
//
